Polylite Taiwan Co., Ltd. AI Stock Analysis
Polylite Taiwan Co., Ltd. (1813) AI Stock Analysis
Polylite Taiwan Co., Ltd.
(TPEx:1813)
Polylite Taiwan scores low primarily because of persistently weak profitability: revenue has shrunk by more than 30% over six years, gross margin is negative, operating losses have occurred every year, and the company returned to a net loss of about NT$48 million. Partially offsetting this are a conservative balance sheet (debt-to-equity near 0.32, equity funding about 73% of assets) and five consecutive years of positive free cash flow, which keep the business self-funding. Technicals reinforce the caution, with the price below all major moving averages and negative MACD momentum, though the deeply depressed RSI suggests selling may be stretched. Valuation adds further pressure, with a P/E above 30 despite loss-making operations and no dividend support. A credible path back to positive gross margins and revenue stabilisation is needed before the score can improve meaningfully.
Polylite Taiwan Co., Ltd. (1813) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 487.34M
- Dividend Yield
- ―
- Average Volume (3M)
- 20.17K
- Price to Earnings (P/E)
- 30.3
- Beta (1Y)
- 0.23
- Revenue Growth
- -6.91%
- EPS Growth
- ―
- Country
- TW
- Employees
- 149
- Sector
- General
- Sector Strength
- 55
- Industry
- Semiconductors
Polylite Taiwan Co., Ltd. Business Overview & Revenue Model
Company Description
Polylite Taiwan Co., Ltd. is an international enterprise engaged in the fabrication, refinement, worldwide trade, and retail of a diverse selection of optical lenses, precision optical devices, and medical instruments. A key part of its product line...
Polylite Taiwan Co., Ltd. Financial Statement Overview
Summary
A clearly split profile. The income statement is the weak link (score 16): revenue has fallen in five of the last six years to roughly NT$304 million, gross margin is negative (about -17%), EBIT has been negative every year, and the company swung back to a net loss of about NT$48 million. The balance sheet is the main source of resilience (score 63): debt-to-equity near 0.32, equity funding roughly 73% of assets, though equity has eroded from about NT$847 million to NT$685 million and ROE is negative at about -7%. Cash flow is the steadiest element (score 56): operating cash flow of about NT$47 million and free cash flow of about NT$37 million, positive for five straight years, but well below 2021 levels. Overall, financial stability buys time, but shrinking sales and negative gross margins point to a fundamentally unprofitable operation.
Income Statement
16Very NegativeBalance Sheet
63PositiveCash Flow
56Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 287.69M | 304.32M | 309.91M | 360.45M | 362.05M | 451.13M |
| Gross Profit | -47.72M | -52.32M | -59.80M | -3.93M | -22.26M | 19.58M |
| EBITDA | -48.33M | -1.81M | -54.00M | -11.38M | 11.54M | 45.52M |
| Net Income | 7.50M | -47.94M | -29.30M | 11.20M | 6.71M | -13.13M |
Balance Sheet | ||||||
| Total Assets | 968.25M | 931.76M | 1.01B | 1.05B | 1.14B | 1.26B |
| Cash, Cash Equivalents and Short-Term Investments | 146.40M | 138.21M | 119.04M | 150.27M | 210.44M | 305.97M |
| Total Debt | 238.04M | 217.53M | 241.96M | 204.99M | 251.25M | 323.77M |
| Total Liabilities | 304.44M | 270.75M | 302.59M | 276.56M | 315.79M | 426.21M |
| Stockholders Equity | 693.34M | 684.54M | 723.73M | 774.95M | 811.94M | 813.72M |
Cash Flow | ||||||
| Free Cash Flow | 61.93M | 36.53M | 30.39M | 36.75M | 16.05M | 60.11M |
| Operating Cash Flow | 67.64M | 46.81M | 35.20M | 46.22M | 31.93M | 78.68M |
| Investing Cash Flow | -16.24M | -10.05M | -67.63M | -9.11M | -14.79M | -19.50M |
| Financing Cash Flow | -12.73M | -18.84M | 13.48M | -97.52M | -99.45M | 29.27M |
Polylite Taiwan Co., Ltd. Peers Comparison
Overall Rating
- TW:181341Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:1813 | 41Neutral | TWD 478.01M | 30.27 | ― | ― | -6.91% | ― |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:1813 | Polylite Taiwan Co., Ltd. | 10.45 | -2.75 | -20.83% | |
| TW:4115 | Sunder Biomedical Tech. Co., Ltd. | 6.97 | -1.43 | -17.02% | |
| TW:4170 | Vectorite Biomedical, Inc. | 11.00 | -2.60 | -19.12% | |
| TW:6660 | HMD Biomedical, Inc. | 12.70 | -11.05 | -46.53% | |
| TW:6999 | Han Biomedical, Inc. | 24.45 | -6.02 | -19.75% | |
| TW:7726 | CARILEX MEDICAL INC. | 32.15 | -3.95 | -10.94% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026